LESLIE WOLF: Open Payments
NPI 1235354572 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,228 in 51 payments from 14 companies in 2025. Trend: 2023 $855 · 2024 $1,518 · 2025 $1,228
Food & beverage: $1,228
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 13 | $360 |
| Lilly USA, LLC | 1 | $122 |
| Gilead Sciences, Inc. | 4 | $116 |
| Regeneron Healthcare Solutions, Inc. | 4 | $96 |
| Janssen Biotech, Inc. | 5 | $96 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $86 |
| GENZYME CORPORATION | 3 | $86 |
| ABBVIE INC. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Phathom Pharmaceuticals, Inc. | 5 | $42 |
Products named: REZDIFFRA, DUPIXENT, OMVOH, TREMFYA, XIFAXAN, VOQUEZNA, IQIRVO, RINVOQ.
Industry payments across NE — which companies pay providers there.
